Wednesday, May 22, 2024
wellness India Expo


Sentynl Therapeutics gets UK MHRA approval for its drug ‘NULIBRY’ to...

NULIBRY® is the first and only treatment in the United Kingdom (UK) for patients with Molybdenum Cofactor Deficiency (MoCD) Type A. MoCD Type A is an ultra-rare, life- threatening genetic disorder

BridgeBio & Sentynl Therapeutics get EU nod for NULIBRY, a therapy...

MoCD Type A is an ultra-rare and progressive condition known to impact less than 150 patients globally with a median survival of four years

US subsidiary of Zydus Lifesciences buys BridgeBio Pharma’s NULIBRY

NULIBRY is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder